218 related articles for article (PubMed ID: 25655608)
21. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
22. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
[No Abstract] [Full Text] [Related]
24. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
[TBL] [Abstract][Full Text] [Related]
25. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
Schwenzer NF; Pfannenberg AC
Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
[TBL] [Abstract][Full Text] [Related]
26. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
27. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
28. PET imaging in lymphoma.
Hutchings M
Expert Rev Hematol; 2009 Jun; 2(3):261-76. PubMed ID: 21082968
[TBL] [Abstract][Full Text] [Related]
29. Current Role of Functional Imaging in the Management of Lymphoma.
Cheson BD; Meignan M
Curr Oncol Rep; 2021 Nov; 23(12):144. PubMed ID: 34735647
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L
Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002
[TBL] [Abstract][Full Text] [Related]
31. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
Thanarajasingam G; Bennani-Baiti N; Thompson CA
Curr Treat Options Oncol; 2016 May; 17(5):24. PubMed ID: 27032646
[TBL] [Abstract][Full Text] [Related]
32. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
33. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?
Hutchings M
Hematology Am Soc Hematol Educ Program; 2012; 2012():322-7. PubMed ID: 23233599
[TBL] [Abstract][Full Text] [Related]
34. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
35. PET/CT in Non-Hodgkin Lymphoma: An Update.
Zanoni L; Bezzi D; Nanni C; Paccagnella A; Farina A; Broccoli A; Casadei B; Zinzani PL; Fanti S
Semin Nucl Med; 2023 May; 53(3):320-351. PubMed ID: 36522191
[TBL] [Abstract][Full Text] [Related]
36. Use of F-18 FDG PET/CT in non-Hodgkin lymphoma with central nervous system involvement.
Cimarelli S; Sebban C; Thiesse P; Sunyach MP; Blay JY; Ghesquières H
Clin Nucl Med; 2011 Jun; 36(6):e45-9. PubMed ID: 21552016
[TBL] [Abstract][Full Text] [Related]
37. FDG PET/CT imaging as a biomarker in lymphoma.
Meignan M; Itti E; Gallamini A; Younes A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):623-33. PubMed ID: 25573631
[TBL] [Abstract][Full Text] [Related]
38. Response assessment in lymphoma.
Hampson FA; Shaw AS
Clin Radiol; 2008 Feb; 63(2):125-35. PubMed ID: 18194687
[TBL] [Abstract][Full Text] [Related]
39. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
Barrington SF; Kluge R
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):97-110. PubMed ID: 28411336
[TBL] [Abstract][Full Text] [Related]
40. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.
Dunleavy K; Mikhaeel G; Sehn LH; Hicks RJ; Wilson WH
Leuk Lymphoma; 2010 Aug; 51 Suppl 1():28-33. PubMed ID: 20658958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
